SCHEMBL143419

SCHEMBL143419

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1CC(=O)NCCNCC(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 9/20 0.54
KDR P35968 8/20 0.54
FGFR1 P11362 7/20 0.54
MET P08581 6/20 0.54
PRKAA2 P54646 4/20 0.54
PRKAA1 Q13131 4/20 0.54
EGFR P00533 3/20 0.54
SRC P12931 2/20 0.54
CDK2 P24941 2/20 0.54
PTK2B Q14289 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
KIT P10721 2/20 0.54
NEK2 P51955 2/20 0.54
PLK4 O00444 1/20 0.54
RIOK3 O14730 1/20 0.54
CASK O14936 1/20 0.54
GAK O14976 1/20 0.54
DCLK1 O15075 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6513207 0.93 KDR (0.47) PDGFRBKDRFGFR1METPRKAA2
SCHEMBL6514631 0.86 KDR (0.56) PDGFRBKDRFGFR1METPRKAA2
SCHEMBL144615 0.86 PDGFRB (0.61) PDGFRBKDRFGFR1METPRKAA2
SCHEMBL142917 0.85 FGFR1 (0.59) PDGFRBKDRFGFR1METPRKAA2
SCHEMBL143097 0.85 KDR (0.66) PDGFRBKDRFGFR1METPRKAA2
SCHEMBL144744 0.84 FGFR1 (0.61) PDGFRBKDRFGFR1METPRKAA2
SCHEMBL144892 0.84 KDR (0.61) PDGFRBKDRFGFR1METPRKAA2
SCHEMBL145631 0.83 SRC (0.57) PDGFRBKDRFGFR1METPRKAA2
SCHEMBL142958 0.83 FGFR1 (0.58) PDGFRBKDRFGFR1METPRKAA2
SCHEMBL143285 0.83 FGFR1 (0.62) PDGFRBKDRFGFR1METPRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 WO disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 PDGFRB 467/4885KDR 1077/4885FGFR1 5/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 PDGFRB 348/4885KDR 398/4885FGFR1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.